Drug Profile
Meningococcal vaccine group Y conjugate - Baxter International
Latest Information Update: 10 Jul 2002
Price :
$50
*
At a glance
- Originator Baxter International
- Class Meningococcal vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Meningococcal group Y infections
Most Recent Events
- 27 Jun 2000 North American Vaccine has been acquired by and merged into Baxter International
- 09 Nov 1999 New profile
- 09 Nov 1999 Preclinical development for Meningococcal group Y infections in USA (Unknown route)